Abstract

T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell malignancy. Here we integrated large-scale profiling data of alterations in gene expression, allelic copy number (CN), and nucleotide sequences in 111 well-characterized patients. Besides prominent signatures of T-cell activation and prevalent clonal variants, we also identify novel hot-spots for CN variability, fusion molecules, alternative transcripts, and progression-associated dynamics. The overall lesional spectrum of T-PLL is mainly annotated to axes of DNA damage responses, T-cell receptor/cytokine signaling, and histone modulation. We formulate a multi-dimensional model of T-PLL pathogenesis centered around a unique combination of TCL1 overexpression with damaging ATM aberrations as initiating core lesions. The effects imposed by TCL1 cooperate with compromised ATM toward a leukemogenic phenotype of impaired DNA damage processing. Dysfunctional ATM appears inefficient in alleviating elevated redox burdens and telomere attrition and in evoking a p53-dependent apoptotic response to genotoxic insults. As non-genotoxic strategies, synergistic combinations of p53 reactivators and deacetylase inhibitors reinstate such cell death execution.

Details

Title
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL
Author
Schrader, A 1 ; Crispatzu, G 1 ; Oberbeck, S 1 ; Mayer, P 1 ; Pützer, S 1 ; J von Jan 1 ; Vasyutina, E 1 ; Warner, K 2 ; Weit, N 1 ; Pflug, N 3 ; Braun, T 1 ; Andersson, E I 4   VIAFID ORCID Logo  ; Yadav, B 4 ; Riabinska, A 5 ; Maurer, B 6 ; Ventura Ferreira, M S 7 ; Beier, F 7 ; Altmüller, J 8 ; Lanasa, M 9 ; Herling, C D 5 ; Haferlach, T 10 ; Stilgenbauer, S 11 ; Hopfinger, G 12 ; Peifer, M 13   VIAFID ORCID Logo  ; Brümmendorf, T H 7 ; Nürnberg, P 8 ; Elenitoba-Johnson, K S J 14 ; Zha, S 15 ; Hallek, M 5 ; Moriggl, R 6   VIAFID ORCID Logo  ; Reinhardt, H C 5 ; M-H Stern 16   VIAFID ORCID Logo  ; Mustjoki, S 4 ; Newrzela, S 17 ; Frommolt, P 18 ; Herling, M 1 

 Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC), Köln, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), UoC, Köln, Germany; CMMC, Center for Molecular Medicine University of Cologne (UoC), Köln, Germany 
 Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC), Köln, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), UoC, Köln, Germany; Senckenberg Institute of Pathology, Goethe-University, Frankfurt/M., Germany 
 Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC), Köln, Germany 
 Hematology Research Unit Helsinki, Department of Medicine and Clinical Chemistry, University of Helsinki and Helsinki University Central Hospital (HUCH), Helsinki, Finland 
 Department of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn, University of Cologne (UoC), Köln, Germany; Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), UoC, Köln, Germany 
 Institute of Animal Breeding and Genetics, University of Veterinary Medicine; Ludwig Boltzmann Institute for Cancer Research, Medical University of Vienna, Vienna, Austria 
 Department of Hematology, Oncology, and Stem Cell Transplantation, RWTH Aachen University Medical School, Aachen, Germany 
 Cologne Center for Genomics, UoC, Germany, Institute of Human Genetics, University of Cologne (UoC), Köln, Germany 
 Duke University Medical Center, Durham, NC, USA 
10  MLL Munich Leukemia Laboratory, Munich, Germany 
11  Department III of Internal Medicine, University Hospital Ulm, Ulm, Germany 
12  Department of Internal Medicine, Bone Marrow Transplantation Unit, Medical University of Vienna, Vienna, Austria 
13  Department of Translational Genomics, UoC, Köln, Germany 
14  Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA 
15  Institute for Cancer Genetics, Department of Pathology and Cell Biology, Herbert Irving Comprehensive Cancer Center, Division of Pediatric Oncology, Department of Pediatrics, Columbia University Medical Center, Columbia University, New York, USA 
16  INSERM U830, Institut Curie, PSL Research University, Paris, France 
17  Senckenberg Institute of Pathology, Goethe-University, Frankfurt/M., Germany 
18  Bioinformatics Core Facility, CECAD, UoC, Köln, Germany 
Pages
1-22
Publication year
2018
Publication date
Feb 2018
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2002472613
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.